Get started

MEI Pharma

Homepage URL: meipharma.com
Alternate name: MEI Pharma Inc.
Description: company in San Diego, United States
Country: US
ROR: 02bgfrc80
Wikidata ID: entity/Q104481250
Crossref ID: 100016282
DOI: 10.13039/100016282
OpenAlex ID: F4320316491
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
2021 · Michael Heuser, Sylvie D. Freeman, et al. · Blood · 829
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019 · Laurie H. Sehn, Alex F. Herrera, et al. · Journal of Clinical Oncology · 812
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
2019 · Tait D. Shanafelt, Xin V. Wang, et al. · New England Journal of Medicine · 771
PDF
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
2019 · Andrew H. Wei, Stephen A. Strickland, et al. · Journal of Clinical Oncology · 710
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
2020 · Amer M Zeidan, Prajwal C Boddu, et al. · The Lancet Haematology · 676
PDF
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
2018 · Eytan M. Stein, Courtney D. DiNardo, et al. · Blood · 344
PDF
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
2021 · Lihua E. Budde, Sarit Assouline, et al. · Journal of Clinical Oncology · 337
PDF
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
2020 · Anthony R. Mato, Lindsey E. Roeker, et al. · Blood · 307
PDF
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2020 · M. Dreyling, M. Ghielmini, et al. · Annals of Oncology · 293
PDF
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
2020 · Connie L. Batlevi, Fushen Sha, et al. · Blood Cancer Journal · 228
PDF
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
2023 · Tanya Siddiqi, David G Maloney, et al. · The Lancet · 223
PDF
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
2023 · David A. Sallman, Monzr M. Al Malki, et al. · Journal of Clinical Oncology · 211
PDF
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
2023 · Nizar J. Bahlis, Caitlin L. Costello, et al. · Nature Medicine · 178
PDF
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
2021 · Kunhwa Kim, Abhishek Maiti, et al. · Cancer · 172
PDF
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
2023 · Karim Fizazi, Arun A. Azad, et al. · Nature Medicine · 163
PDF
When should we order a next generation sequencing test in a patient with cancer?
2020 · Ramon Colomer, Rebeca Mondejar, et al. · EClinicalMedicine · 158
PDF
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
2018 · Maximilian Stahl, Michelle DeVeaux, et al. · Blood Advances · 149
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
2023 · Michael L. Wang, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 138
PDF
Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
2022 · Paolo Ghia, Andrzej Pluta, et al. · HemaSphere · 119
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
2023 · Nancy L. Bartlett, Sarit Assouline, et al. · Blood Advances · 114
PDF
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
2024 · Laurie H. Sehn, Nancy L. Bartlett, et al. · Blood · 110
PDF
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
2017 · Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, et al. · Cancer · 107
PDF
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
2024 · T.M. Kim, M. Taszner, et al. · Annals of Oncology · 103
PDF
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
2020 · Lindsey E. Roeker, Peter Dreger, et al. · Blood Advances · 92
PDF
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
2022 · Joanna Zurko, Jeremy Ramdial, et al. · Haematologica · 91
PDF
Works count: 307
Citation count: 11,130
H-index: 45
I10-index: 130
2-year mean citedness: 11.59
Awards count: 0
Year
Topic
Type